Literature DB >> 27015431

Six-minute walk test is reliable and valid in spinal muscular atrophy.

Sally Dunaway Young1,2, Jacqueline Montes3,4, Samantha S Kramer5, Jonathan Marra3, Rachel Salazar3, Rosangel Cruz3, Claudia A Chiriboga3, Carol Ewing Garber5, Darryl C De Vivo3.   

Abstract

INTRODUCTION: The Six-Minute Walk Test (6MWT) was adopted as a clinical outcome measure for ambulatory spinal muscular atrophy (SMA). However, a systematic review of measurement properties reported significant variation among chronic pediatric conditions. Our purpose was to assess the reliability/validity of the 6MWT in SMA.
METHODS: Thirty participants performed assessments, including the 6MWT, strength, and function. Reproducibility was evaluated by intraclass correlation coefficients. Criterion/convergent validity were determined using Pearson correlation coefficients.
RESULTS: Test-retest reliability was excellent. The 6MWT was associated positively with peak oxygen uptake, Hammersmith Functional Motor Scale Expanded (HFMSE), lower extremity manual muscle testing, knee flexion hand-held dynamometry, and inversely with 10-m walk/run. The 6MWT discriminates between disease severity, unlike the HFMSE.
CONCLUSIONS: This study documents measurement properties of reproducibility, positive criterion validity, and convergent validity with established clinical assessments and reaffirms the value of the 6MWT as a pivotal outcome measure in SMA clinical trials. Muscle Nerve 54: 836-842, 2016.
© 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  Six-Minute Walk Test; clinical trials; outcome measure; reliability; spinal muscular atrophy; validation

Mesh:

Year:  2016        PMID: 27015431     DOI: 10.1002/mus.25120

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  33 in total

Review 1.  Strength Testing in Motor Neuron Diseases.

Authors:  Jeremy M Shefner
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

2.  Development of new outcome measures for adult SMA type III and IV: a multimodal longitudinal study.

Authors:  Giorgia Querin; Timothée Lenglet; Rabab Debs; Tanya Stojkovic; Anthony Behin; François Salachas; Nadine Le Forestier; Maria Del Mar Amador; Gaëlle Bruneteau; Pascal Laforêt; Sophie Blancho; Véronique Marchand-Pauvert; Peter Bede; Jean-Yves Hogrel; Pierre-François Pradat
Journal:  J Neurol       Date:  2021-01-02       Impact factor: 4.849

3.  Six-minute walk test is reliable and sensitive in detecting response to therapy in CIDP.

Authors:  Emanuele Spina; Antonietta Topa; Rosa Iodice; Stefano Tozza; Lucia Ruggiero; Raffaele Dubbioso; Marcello Esposito; Pasquale Dolce; Lucio Santoro; Fiore Manganelli
Journal:  J Neurol       Date:  2019-02-05       Impact factor: 4.849

Review 4.  Disease Modifying Therapies for the Management of Children with Spinal Muscular Atrophy (5q SMA): An Update on the Emerging Evidence.

Authors:  Helgi Thor Hjartarson; Kristofer Nathorst-Böös; Thomas Sejersen
Journal:  Drug Des Devel Ther       Date:  2022-06-16       Impact factor: 4.319

5.  Limitations of 6-minute walk test reference values for spinal muscular atrophy.

Authors:  Ashley M Goodwin; Kayla M D Cornett; Marnee J McKay; Joshua Burns; Carol Ewing Garber; Darryl C De Vivo; Jacqueline Montes
Journal:  Muscle Nerve       Date:  2020-01-16       Impact factor: 3.217

6.  Diminished muscle oxygen uptake and fatigue in spinal muscular atrophy.

Authors:  Jacqueline Montes; Ashley M Goodwin; Michael P McDermott; David Uher; Feliz Marie Hernandez; Kayla Coutts; Julia Cocchi; Margarethe Hauschildt; Kayla M Cornett; Ashwini K Rao; Umrao R Monani; Carol Ewing Garber; Darryl C De Vivo
Journal:  Ann Clin Transl Neurol       Date:  2021-03-31       Impact factor: 5.430

Review 7.  Physical exercise training for type 3 spinal muscular atrophy.

Authors:  Bart Bartels; Jacqueline Montes; W Ludo van der Pol; Janke F de Groot
Journal:  Cochrane Database Syst Rev       Date:  2019-03-01

8.  International Workshop:: Outcome measures and clinical trial readiness in primary mitochondrial myopathies in children and adults. Consensus recommendations. 16-18 November 2016, Rome, Italy.

Authors:  Michelangelo Mancuso; Robert McFarland; Thomas Klopstock; Michio Hirano
Journal:  Neuromuscul Disord       Date:  2017-09-08       Impact factor: 4.296

9.  Neuroanatomical Models of Muscle Strength and Relationship to Ambulatory Function in Spinal Muscular Atrophy.

Authors:  Rafael Rodriguez-Torres; Julia Fabiano; Ashley Goodwin; Ashwini K Rao; Stacy Kinirons; Darryl De Vivo; Jacqueline Montes
Journal:  J Neuromuscul Dis       Date:  2020

10.  Nusinersen in pediatric and adult patients with type III spinal muscular atrophy.

Authors:  Maria Carmela Pera; Giorgia Coratti; Francesca Bovis; Marika Pane; Amy Pasternak; Jacqueline Montes; Valeria A Sansone; Sally Dunaway Young; Tina Duong; Sonia Messina; Irene Mizzoni; Adele D'Amico; Matthew Civitello; Allan M Glanzman; Claudio Bruno; Francesca Salmin; Simone Morando; Roberto De Sanctis; Maria Sframeli; Laura Antonaci; Anna Lia Frongia; Annemarie Rohwer; Mariacristina Scoto; Darryl C De Vivo; Basil T Darras; John Day; William Martens; Katia A Patanella; Enrico Bertini; Francesco Muntoni; Richard Finkel; Eugenio Mercuri
Journal:  Ann Clin Transl Neurol       Date:  2021-06-24       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.